In a significant advancement for pediatric medicine, the U.S. Food and Drug Administration (FDA) has officially granted approval for ViiV Healthcare’s Tivicay PD (dolutegravir) for the treatment of HIV-1 in infants weighing as little as 2 kilograms (approximately 4.4 pounds). This decision marks a critical turning point in the management of perinatally acquired HIV, effectively removing the minimum-age requirement that previously limited the drug’s use to infants at least four weeks old. By expanding the label to include neonates from birth, the regulatory action addresses a long-standing therapeutic gap, ensuring that the most vulnerable patients have access to potent, well-tolerated antiretroviral therapy (ART) during the earliest, most precarious weeks of life.
The Evolution of Tivicay: A Chronological Overview
The journey of dolutegravir from an adult medication to a cornerstone of pediatric HIV care has been defined by a systematic, data-driven expansion of its label.
- August 2013: The FDA first approved Tivicay (dolutegravir) for use in adults and adolescents aged 12 years or older, provided they met a minimum weight threshold of 40 kilograms (88.2 pounds). This established the drug as a powerful integrase strand transfer inhibitor (INSTI) in the global fight against HIV.
- 2020: Recognizing the need for child-friendly formulations, the FDA approved the dispersible tablet form—Tivicay PD. This formulation was cleared for patients at least four weeks of age who weighed at least 3 kilograms (6.6 pounds).
- August 2026: The FDA expanded the indication for Tivicay PD. The new approval permits the use of the drug in newborns weighing at least 2 kilograms, eliminating the previous four-week age restriction. This development solidifies dolutegravir as the first second-generation integrase inhibitor specifically approved for this neonate demographic.
Clinical Foundations: The IMPAACT 2023 Study
The regulatory approval was not a sudden development but the culmination of rigorous clinical investigation. The cornerstone of the FDA’s decision was the NIH-funded IMPAACT 2023 study, a multicenter Phase 1 trial designed to assess the safety, tolerability, and pharmacokinetics (PK) of dolutegravir in the first six weeks of life.
The study enrolled 48 mother-infant pairs across clinical sites in the United States, Thailand, and South Africa. The trial focused on infants exposed to HIV-1 who weighed at least 2 kilograms. These newborns received Tivicay PD from birth for up to six weeks, alongside standard-of-care antiretroviral regimens typically employed to prevent vertical transmission of the virus.
The findings, which were later corroborated by preliminary data presented at the Conference on Retroviruses and Opportunistic Infections (CROI) in 2025, were compelling. Researchers observed that the drug levels achieved in these newborns were consistent with adult exposures associated with therapeutic efficacy. Furthermore, the safety profile identified during the 16-week follow-up period mirrored the safety data seen in older pediatric patients and adults.
A specialized cohort of 15 full-term infants, who began treatment within the first five days of life, demonstrated the feasibility of early intervention. These infants, weighing between 2.3 and 3.6 kilograms, followed a regimen of 5-mg Tivicay PD administered every other day for the first two weeks, transitioning to daily dosing thereafter. This dosing strategy successfully bridged the gap between birth and established pediatric protocols.
The Urgent Need: Addressing the Global HIV Burden
The necessity for this expanded approval is underscored by sobering global health statistics. According to data from UNICEF and other global health organizations, the mortality rate for infants living with HIV who do not receive timely treatment is devastating: roughly half of these children do not survive past their second birthday.
In the United States, while the rate of perinatal transmission has been successfully suppressed to 1% or less, the condition remains a critical health concern. Since 2018, there have been fewer than 50 cases of perinatally acquired HIV annually among children born in the U.S. However, for those few, the difference between a lifetime of health and a life-threatening illness rests on the availability of immediate, effective, and tolerable treatment options.
"For too long, newborns living with HIV have had too few treatment options designed and studied to meet their unique needs, despite the importance of starting treatment as early as possible," stated Diana F. Clarke, Pharm.D., a professor at the Boston University School of Medicine and lead investigator of the IMPAACT 2023 study. Her assessment highlights a shift in clinical philosophy: moving away from waiting for an infant to reach a certain age or weight, and instead moving toward immediate intervention to suppress viral replication before it can cause irreversible immune system damage.
Financial Implications and Market Context
While Tivicay PD represents a major clinical victory, it operates within a complex commercial landscape for its parent company, GSK (ViiV Healthcare’s majority shareholder).
The standalone Tivicay brand has reached a state of relative maturity, with sales plateauing. GSK reported £1.323 billion in global Tivicay sales for the full year 2025, a slight decrease from the £1.350 billion reported in 2024. This trend continued into the first half of 2026, with sales of £629 million, reflecting a modest year-over-year decline.
However, these figures do not paint the full picture of GSK’s HIV franchise. The company’s broader portfolio remains a significant engine for growth, recording £7.687 billion in 2025—an 11% increase at constant exchange rates. The success of newer, long-acting therapies like Cabenuva and Apretude, as well as the oral regimen Dovato, has effectively offset the natural decline of older, first-generation HIV products. The approval of Tivicay PD for newborns serves as a strategic reinforcement of the brand’s utility, ensuring that ViiV maintains a presence in the neonatal space while shifting the bulk of its commercial focus toward its next-generation long-acting and two-drug regimens.
Implications for Clinical Practice
The FDA’s approval of Tivicay PD for newborns changes the standard of care in three fundamental ways:
- Dosing Flexibility: By providing a clear framework for dosing in newborns weighing as little as 2 kilograms, the FDA has removed the ambiguity that often surrounds the "off-label" use of medications in neonates. Pediatricians can now prescribe with confidence, knowing the dosage has been vetted through comprehensive pharmacokinetic modeling.
- Early Viral Suppression: Starting treatment in the first few days of life is critical. By enabling the use of a second-generation integrase inhibitor, this approval allows for faster viral load reduction compared to older, first-generation antiretrovirals, which is essential for protecting the rapidly developing neonatal immune system.
- Global Scalability: While this approval is specific to the U.S. market, the data generated by the IMPAACT 2023 study—conducted in diverse international settings—serves as a blueprint for global health initiatives. The ability to treat the smallest, most fragile infants will likely influence international treatment guidelines, potentially improving survival rates for children in resource-limited settings where HIV transmission remains higher.
Conclusion
The expansion of the Tivicay PD label represents a triumph of translational science. By transitioning from the laboratory to multicenter clinical trials and ultimately to a label change, ViiV Healthcare and the research community have successfully closed a critical loophole in pediatric HIV care.
As clinicians move forward, the focus will likely shift toward optimizing long-term outcomes for these infants. While the current approval provides the necessary tools for initial treatment, the ongoing challenge remains ensuring that every newborn exposed to HIV is identified immediately and transitioned onto these effective therapies. The integration of Tivicay PD into neonatal protocols is not just a regulatory milestone; it is a vital step toward the broader goal of eliminating pediatric HIV and ensuring that every child, regardless of their birth weight or circumstances, has the opportunity for a healthy start.
About the Author
